Reply - 04/08/18
Doi : 10.1016/j.jaci.2018.02.030
Njira L. Lugogo, MD a 
, Cynthia Green, PhD b, Monica Kraft, MD c
, Cynthia Green, PhD b, Monica Kraft, MD c a Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich
b Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC
c Department of Medicine, University of Arizona, Tucson, Ariz
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: N. L. Lugogo reports institutional grant funding from the National Institutes of Health (NIH); reports institutional funding for clinical trials from GSK, AstraZeneca, and Sanofi; has received consulting fees from AstraZeneca, GSK, and TEVA; has received institutional funding from Genentech for an investigator-initiated study in the past (3 years ago); and has received an educational grant from Grifols. M. Kraft reports institutional grants from the NIH, Chiesi, and Sanofi; reports receiving consulting fees from Teva Pharmaceuticals and AstraZeneca; and reports feed from the FDA: LABA Trials Joint DSMB and book royalties from Elsevier. C. Green declares no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 2
P. 713-714 - août 2018 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?